TrialFind
SearchAbout
Saved trials

Filters

Sort by

Recruitment

Status

Phase

Age group

TrialFind

Making clinical research accessible to everyone. Search 500,000+ trials in plain English.

NavigationHomeSearch TrialsAboutSaved Trials
Data & LegalClinicalTrials.govPrivacyRegulatory infoContact

© 2025 TrialFind. Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

RecruitingN/A

Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has sho

Amsterdam, Netherlands
View details
TerminatedPhase 1

A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.

This is an open label, PET study in healthy male subjects to determine if GSK2647544 is able to cross the blood-brain-barrier. The study will use GSK2647544 radiolabelled with fluorine-18 (\[18F\] GSK2647544) to determine the ratio of the c

London, United Kingdom
View details
Load more trials
Completed

Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are recognized as a major health concern at the present time. There is information in magnetic resonance imaging (MRI) studies regarding th

Multiple locations
View details
CompletedPhase 2

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.

Atlanta, Georgia, United States+1 more
View details
CompletedPhase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).

New Haven, Connecticut, United States
View details
UnknownN/A

CLearing Alzheimer's Disease Molecular Pathology Without Medications

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and de

Multiple locations
View details
CompletedPhase 1

An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress and treatmen

Stockholm, Sweden+1 more
View details
CompletedN/A

Virtual Environment to Aid Cognitive Stimulation of Elderly People With Early Alzheimer's

This research was carried out with the objective of verifying the possibility of intervention through cognitive training protocols to assist in the stimulation of neurons and to delay the degradation resulting from Alzheimer's disease in it

Mogi das Cruzes, São Paulo, Brazil
View details
TerminatedN/A

Decision Making Tool for Firearm Storage

This is a one-arm pilot study testing the feasibility and acceptability of a decision aid about safe firearm storage.

Seattle, Washington, United States
View details
UnknownN/A

Assessing Neurovisual Function in Patients With Cognitive Impairment

The aim of this study is to measure fitness to drive in patients with a visual and a cognitive impairment. To do so, Ocusweep is used in patients with glaucoma and Mild Cognitive Impairment.

Turku, Finland
View details
Active, not recruitingPhase 3

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict ri

Chandler, Arizona, United States+48 more
View details
Active, not recruitingN/A

48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease

Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.

Jacksonville, Florida, United States
View details
UnknownN/A

Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease

This study protocol proposes an EEG based neurofeedback (EEG-NFB) technique to upregulate the posterior cingulate cortex (PCC) in patients suffering from mild cognitive impairment (MCI) and early Alzheimer's disease (AD). EEG-NFB has been s

Beersheba, Israel
View details
Recruiting

Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders

The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.

Rouen, France
View details
Unknown

Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.

Brentwood, Tennessee, United States
View details
CompletedPhase 2

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

Based on prior published pilot studies, the investigators have initiated a larger, multi-site placebo-controlled clinical trial with Alzheimer's disease (AD) patients and individuals diagnosed with Mild Cognitive Impairment (MCI), with the

Naples, Florida, United States+7 more
View details
RecruitingPhase 4

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Miami, Florida, United States+4 more
View details
CompletedPhase 4

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm\^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm\^2 patch) in patients with Severe Dementia of the

Tempe, Arizona, United States+94 more
View details
CompletedN/A

Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment

The purpose of this research study is to investigate the relationship between light, the thickness of the pigment at the back of your eye, melatonin levels, and memory. The study will investigate whether changing light distribution pattern

Menands, New York, United States
View details
Completed

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3

St. Petersburg, Florida, United States
View details